Skip to main navigation Skip to search Skip to main content

Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study.

Pär Stattin, Herman Adlercreutz, Leena Tenkanen, Egil Jellum, Sonja Lumme, Göran Hallmans, Sverre Harvei, Lyly Teppo, Katariina Stumpf, Tapio Luostarinen, Matti Lehtinen, Joakim Dillner, Matti Hakama

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)124-129
JournalInternational Journal of Cancer
Volume99
Issue number1
DOIs
Publication statusPublished - 2002

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Subject classification (UKÄ)

  • Cancer and Oncology

Free keywords

  • Sweden: epidemiology
  • 4-Butyrolactone: analogs & derivatives
  • 4-Butyrolactone: blood
  • Case-Control Studies
  • Cohort Studies
  • Estrogens: blood
  • Finland: epidemiology
  • Non-U.S. Gov't
  • Fluoroimmunoassay
  • Human
  • Lignans: blood
  • Male
  • Middle Aged
  • Norway: epidemiology
  • Prospective Studies
  • Prostatic Neoplasms: blood
  • Prostatic Neoplasms: epidemiology
  • Risk Factors
  • Support

Cite this